CHLOROPYRAMINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H20ClN3
Molecular Weight	289.803
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCN(CC1=CC=C(Cl)C=C1)C2=CC=CC=N2

InChI

InChIKey=ICKFFNBDFNZJSX-UHFFFAOYSA-N

InChI=1S/C16H20ClN3/c1-19(2)11-12-20(16-5-3-4-10-18-16)13-14-6-8-15(17)9-7-14/h3-10H,11-13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C16H20ClN3
Molecular Weight	289.803
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.sopharma.com/allergosan.php | http://adisinsight.springer.com/drugs/800033511 | https://www.ncbi.nlm.nih.gov/pubmed/19610651

Chloropyramine is an antagonist of H1 histamine receptors. It is indicated for the treatment of various forms of allergic reactions. Chloropyramine is a drug capable of (1) inhibiting the biochemical function of VEGFR-3 and FAK, (2) inhibiting proliferation of a diverse set of cancer cell types in vitro, and (3) reducing tumor growth in vivo.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: http://omedicine.info/en/suprastin.html \| https://www.drugbank.ca/drugs/DB08800 \| http://www.auburn.edu/~deruija/hist_antihis.pdf	Antagonist 2778
Focal adhesion kinase 1 15 Target ID: CHEMBL2695 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19610651 \| https://www.ncbi.nlm.nih.gov/pubmed/23868727	Binding Agent 1064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: http://adisinsight.springer.com/drugs/800033511	Primary		Preclinical	Unknown Approved Use Unknown
Allergy 44 Sources: https://www.sopharma.com/allergosan.php http://omedicine.info/en/suprastin.html https://euromeds-doctor.com/en/product/chloropyramine/synopen	Primary		Approved 8429	ALLERGOSAN Approved Use In the form of solution for injection, it is used in: acute allergic reactions related to urticaria treatment (due to foods, medicines, helminthes, etc.) and insect bite; in allergic reactions of general type (anaphylactic shock, serum disease, Quincke’s edema), when the product is used as a part of the complex therapy. In the form of tablets: for treatment of allergic rhinitis, conjunctivities, hay fever, drug and food allergy, allergic reactions after insect bite. In the form of ointment or cream it is used for treatment of allergic skin reactions.

PubMed

Title	Date	PubMed
Actions of endothelin and corticotropin releasing factor in the guinea-pig ileum: no evidence for an interaction with capsaicin-sensitive neurons.	2003 Aug	12906840
Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis.	2005 Sep-Oct	16287551
Characterization of histamine-induced relaxation in pre-contracted rat aorta.	2009 Apr	19271142
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.	2009 Aug 13	19610651
[Discriminant function analysis in the assessment of laboratory test data in the correction of traditional therapy for mild icteric form of viral hepatitis B in children with food allergy].	2010 Jun	20734860

Patents

Sample Use Guides

In Vivo Use Guide

Composition: One ampoule of 2 ml contains 20 mg chloropyramine hydrochloride (10 mg/ml). One coated tablet contains 25 mg chloropyramine hydrochloride. 1 g of ointment (1%) contains 10 mg chloropyramine hydrochloride. 1 g of cream (1%) contains 10 mg chloropyramine hydrochloride. Dosage and administration: Parenteral administration: in severe allergic reactions 1-2 ampoules intramuscularly or intravenously. Oral administration: adults - 25 mg (1 tabl.) 3-4 times daily (up to 150 mg, if necessary); children over 5 years: 1 tablet, 2-3 times daily. External application: affected area should be treated once or several times a day by applying a thin layer of ointment or cream.

Route of Administration: Other

In Vitro Use Guide

SKN-AS and SK-N-BE(2) neuroblastoma cells were treated with varying concentrations of chloropyramine hydrochloride (C4) for 24 h and cellular viability was measured. Both cell lines demonstrated a decrease in survival that was signifi-cant at 100 μM concentration. The calculated LC50 for C4 was similar in the two cell lines at 170 μM in the SK-N-AS cell line and 144 mM in the SK-N-BE(2) cell line.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:32:52 GMT 2023` Edited by `admin` on `Fri Dec 15 16:32:52 GMT 2023`
Record UNII	2K3L8O9SOV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLOROPYRAMINE

Official Name

English

chloropyramine [INN]

Common Name

English

2-((P-CHLOROBENZYL)(2-DIMETHYLAMINOETHYL)AMINO)PYRIDINE

Common Name

English

Chloropyramine [WHO-DD]

Common Name

English

NSC-241038

Code

English

CHLOROPYRAMINE [MI]

Common Name

English

HALOPYRAMINE

Common Name

English

Classification Tree Code System Code

WHO-ATC

R06AC03